Interaction of the NRF2 and p63 transcription factors promotes keratinocyte proliferation in the epidermis.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
19 04 2021
Historique:
accepted: 03 03 2021
revised: 27 02 2021
received: 01 10 2020
pubmed: 26 3 2021
medline: 13 5 2021
entrez: 25 3 2021
Statut: ppublish

Résumé

Epigenetic regulation of cell and tissue function requires the coordinated action of transcription factors. However, their combinatorial activities during regeneration remain largely unexplored. Here, we discover an unexpected interaction between the cytoprotective transcription factor NRF2 and p63- a key player in epithelial morphogenesis. Chromatin immunoprecipitation combined with sequencing and reporter assays identifies enhancers and promoters that are simultaneously activated by NRF2 and p63 in human keratinocytes. Modeling of p63 and NRF2 binding to nucleosomal DNA suggests their chromatin-assisted interaction. Pharmacological and genetic activation of NRF2 increases NRF2-p63 binding to enhancers and promotes keratinocyte proliferation, which involves the common NRF2-p63 target cyclin-dependent kinase 12. These results unravel a collaborative function of NRF2 and p63 in the control of epidermal renewal and suggest their combined activation as a strategy to promote repair of human skin and other stratified epithelia.

Identifiants

pubmed: 33764436
pii: 6188351
doi: 10.1093/nar/gkab167
pmc: PMC8053124
doi:

Substances chimiques

NF-E2-Related Factor 2 0
NFE2L2 protein, human 0
TP63 protein, human 0
Transcription Factors 0
Tumor Suppressor Proteins 0
CDK12 protein, human EC 2.7.11.22
Cyclin-Dependent Kinases EC 2.7.11.22

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3748-3763

Subventions

Organisme : Medical Research Council
ID : MR/P009700/1
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Dev Cell. 2018 Jul 16;46(2):145-161.e10
pubmed: 30016619
Free Radic Biol Med. 2015 Nov;88(Pt B):243-252
pubmed: 25912479
EMBO J. 2011 Jun 1;30(11):2219-32
pubmed: 21522133
Int J Mol Sci. 2019 Aug 08;20(16):
pubmed: 31398789
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3255-60
pubmed: 17360634
Methods Mol Biol. 2020;2109:125-145
pubmed: 31502220
Dev Cell. 2012 Dec 11;23(6):1238-46
pubmed: 23237955
J Dermatol Sci. 2004 Feb;34(1):3-9
pubmed: 14757276
J Cell Physiol. 1996 Aug;168(2):442-52
pubmed: 8707880
Sci Rep. 2016 Feb 25;6:21455
pubmed: 26911346
EMBO Rep. 2015 Jul;16(7):863-78
pubmed: 26034101
Mol Cell Biol. 2006 Apr;26(8):3308-18
pubmed: 16581802
Cell Signal. 2008 Mar;20(3):493-505
pubmed: 18160256
J Clin Invest. 2015 Apr;125(4):1557-68
pubmed: 25774506
Development. 2017 Dec 15;144(24):4588-4603
pubmed: 29113991
Hum Mol Genet. 2013 Feb 1;22(3):531-43
pubmed: 23108156
Diabetes. 2016 Mar;65(3):780-93
pubmed: 26718502
Nat Chem Biol. 2016 Oct;12(10):876-84
pubmed: 27571479
Cell Rep. 2014 Jul 24;8(2):514-27
pubmed: 25043190
EMBO Rep. 2019 Sep;20(9):e47592
pubmed: 31347271
Nat Genet. 2003 Nov;35(3):238-45
pubmed: 14517554
Nat Commun. 2019 Oct 14;10(1):4676
pubmed: 31611556
J Invest Dermatol. 2012 Nov;132(11):2505-21
pubmed: 22763788
PLoS Genet. 2016 Jan 25;12(1):e1005800
pubmed: 26808544
Am J Pathol. 2019 Mar;189(3):568-579
pubmed: 30593821
Trends Genet. 2012 Jun;28(6):276-84
pubmed: 22487374
Eur J Cell Biol. 2004 Dec;83(11-12):631-45
pubmed: 15679108
Nucleic Acids Res. 2010 Sep;38(17):5718-34
pubmed: 20460467
Free Radic Biol Med. 2015 Nov;88(Pt B):93-100
pubmed: 26117331
EMBO Mol Med. 2012 May;4(5):364-79
pubmed: 22383093
Mol Cell Biol. 2006 May;26(10):3773-84
pubmed: 16648473
J Immunol. 2016 Jun 1;196(11):4663-70
pubmed: 27183581
J Invest Dermatol. 2010 May;130(5):1249-57
pubmed: 20090763
Nature. 2009 Sep 10;461(7261):199-205
pubmed: 19741700
Nat Commun. 2014 Oct 06;5:5099
pubmed: 25283360
Nucleic Acids Res. 2012 Nov 1;40(20):10228-39
pubmed: 22965115
EMBO Mol Med. 2014 Apr;6(4):442-57
pubmed: 24503019
Stem Cell Reports. 2016 Apr 12;6(4):618-632
pubmed: 27050947
Oxid Med Cell Longev. 2019 Jul 14;2019:9372182
pubmed: 31396308
Nucleic Acids Res. 2012 Aug;40(15):7416-29
pubmed: 22581777
Exp Dermatol. 2009 Dec;18(12):1016-21
pubmed: 19555433
Neurobiol Dis. 2015 Jan;73:275-88
pubmed: 25315682
Mol Cell Biol. 2002 Aug;22(15):5492-505
pubmed: 12101242
Nature. 2015 Nov 19;527(7578):384-8
pubmed: 26550823
Nucleic Acids Res. 2012 Aug;40(15):7190-206
pubmed: 22573176
Mol Cell. 1998 Sep;2(3):305-16
pubmed: 9774969
Free Radic Biol Med. 2017 Nov;112:578-586
pubmed: 28870520
Gene Ther. 2013 Sep;20(9):949-57
pubmed: 23615186

Auteurs

Svitlana Kurinna (S)

Division of Cell Matrix Biology and Regenerative Medicine, FBMH, University of Manchester, M13 9PT, United Kingdom.

Kristin Seltmann (K)

Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Andreas L Bachmann (AL)

Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Andreas Schwendimann (A)

Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Lalitha Thiagarajan (L)

Division of Cell Matrix Biology and Regenerative Medicine, FBMH, University of Manchester, M13 9PT, United Kingdom.

Paulina Hennig (P)

Department of Dermatology, University Hospital Zurich, 8006 Zurich, Switzerland.

Hans-Dietmar Beer (HD)

Department of Dermatology, University Hospital Zurich, 8006 Zurich, Switzerland.

Maria Rosaria Mollo (MR)

CEINGE Biotecnologie Avanzate, Naples, Italy, University of Naples Federico II, 80131 Naples, Italy.

Caterina Missero (C)

CEINGE Biotecnologie Avanzate, Naples, Italy, University of Naples Federico II, 80131 Naples, Italy.

Sabine Werner (S)

Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH